Table 4
Influence of interval length (false negative interval cancers excluded)
| Length of interval (months) | ||||||||
|---|---|---|---|---|---|---|---|---|
| 0–12 | 13–24 | 25–36 | Significance | |||||
| *Invasive cancers only; †malignant phyllodes tumour; ‡Nottingham prognostic index. | ||||||||
| Calc, calculated. | ||||||||
| In situ | 3 | (10%) | 0 | 0 | ||||
| Invasive | 28 | (90%) | 31 | (100%) | 23 | (100%) | ||
| Median size (mm)* | 18.9 | 21.6 | 17.7 | p=0.3 | ||||
| Grade* | 1 | 6 | (21%) | 7 | (23%) | 6 | (26%) | |
| 2 | 5 | (18%) | 9 | (29%) | 6 | (26%) | ||
| 3 | 16 | (57%) | 15 | (48%) | 11 | (48%) | ||
| Ungraded† | 1 | (4%) | 0 | 0 | p=0.8 | |||
| Vascular invasion* | Absent | 16 | (57%) | 18 | (58%) | 20 | (87%) | |
| Present | 12 | (43%) | 13 | (42%) | 3 | (13%) | p=0.04 | |
| Number of positive lymph nodes* | 0 | 18 | (64%) | 15 | (48%) | 11 | (48%) | |
| 1–3 | 5 | (18%) | 10 | (32%) | 3 | (13%) | ||
| >3 | 2 | (7%) | 3 | (10%) | 3 | (13%) | ||
| Not sampled | 3 | (11%) | 3 | (10%) | 6 | (26%) | p=0.4 | |
| NPI*‡ | Good | 6 | (21%) | 9 | (29%) | 5 | (22%) | |
| Moderate | 15 | (54%) | 12 | (39%) | 9 | (39%) | ||
| Poor | 4 | (14%) | 7 | (23%) | 3 | (13%) | ||
| Not calc | 3 | (11%) | 3 | (10%) | 6 | (26%) | p=0.6 | |
